Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, today announced results ...

Application error: a client-side exception has occurred (see the browser console for more information).

Two international genitourinary pathology societies have published a white paper calling for improvements in the detection and diagnosis of indolent prostate cancers (PCs). According to the new ...

A newer type of prostate cancer scan called 64 Cu-SAR-bisPSMA found more than twice as many cancer spots as a commonly used PSMA PET scan in men whose prostate-specific antigen (PSA) was rising after ...

A hydroablation device for benign prostatic hyperplasia showed promise as a potential treatment aid for early prostate cancer in a small Chinese study. The proportion of patients with detectable ...

In a randomized trial of men with a single suspicious lesion on MRI, targeted perilesional biopsy matched standard targeted and systematic biopsy for detecting clinically significant prostate cancer - ...

Results from the phase 2 Daro-PET study (NCT05900973) showed that prostate-specific membrane antigen (PSMA) expression was boosted with short-course darolutamide (Nubeqa) in patients with high-risk ...

The methods of diagnosing and treating localised prostate cancer has changed significantly in the last two decades.